Epstein's pal returns to biotech, Prasad's FDA exit part deux, and more news from The Readout
Want to stay on top of the science and politics driving biotech today?
Sign up
to get our biotech newsletter in your inbox.
Cancer researchers have discovered that a notorious oncogene may occasionally wind up exposed on the outside of tumor cells, hinting at a surprising new immunotherapy target.
Meanwhile, Trump continues to win the messaging war on drug pricing, and biotech’s social circles get awkward again with an Epstein-linked investor’s return.
Continue to STAT+ to read the full story…
— Source: STAT News (https://www.statnews.com/2026/03/13/biotech-news-grail-ceo-steps-down-after-trial-setback/)
